[1]
|
Berggren, M., Gallegos, A., Gasdaska, J.R., Gasdaska, P.Y., Warneke, J. and Powis, G. (1996) Thioredoxin and Thi-oredoxin Reductase Gene Expression in Human Tumors and Cell Lines, and the Effects of Serum Stimulation and Hypoxia. Anticancer Research, 16, 3459-3466.
|
[2]
|
Lincoln, D.T., Emadi, E.M.A., Tonissen, K.F. and Clarke, F.M. (2003) The Thioredoxin-Thioredoxin Reductase System: Over-Expression in Human Cancer. Anticancer Research, 23, 2425-2433.
|
[3]
|
Soini, Y., Kahlos, K., Napankangas, U., Kaarteenaho-Wiik, R., Saily, M., Koistinen, P., et al. (2001) Widespread Expression of Thioredoxin and Thioredoxin Reductase in Non-Small Cell Lung Carcinoma. Clinical Cancer Research, 7, 1750-1757.
|
[4]
|
Nguyen, P., Awwad, R.T., Smart, D.D.K., Spitz, D.R. and Gius, D. (2006) Thioredoxin Reductase as a Novel Molecular Target for Cancer Therapy. Cancer Letters, 236, 164-174. http://dx.doi.org/10.1016/j.canlet.2005.04.028
|
[5]
|
Kahlos, K., Soini, Y., Saily, M., Koistinen, P., Kakko, S., Paakko, P., et al. (2001) Up-Regulation of Thioredoxin and Thioredoxin Reductase in Human Malignant Pleural Mesothelioma. International Journal of Cancer, 95, 198-204.
http://dx.doi.org/10.1002/1097-0215(20010520)95:3<198::AID-IJC1034>3.0.CO;2-F
|
[6]
|
Kemerdere, R., Kacira, T., Hanimoglu, H., Kucur, M., Tanriverdi, T. and Canbaz, B. (2013) Tissue and Plasma Thi-oredoxin Reductase Expressions in Patients with Glioblastoma Multiforme. Journal of Neurological Surgery Part A—Central European Neuro-surgery, 74, 234-238.
|
[7]
|
Lincoln, D.T., Al-Yatama, F., Mohammed, F.M.A., Al-Banaw, A.G., Al-Bader, M., Burge, M., et al. (2010) Thiore-doxin and Thioredoxin Reductase Expression in Thyroid Cancer Depends on Tumour Aggressiveness. Anticancer Research, 30, 767-775.
|
[8]
|
Iwasawa, S., Yamano, Y., Takiguchi, Y., Tanzawa, H., Tatsumi, K. and Uzawa, K. (2011) Upregulation of Thioredox-in Reductase 1 in Human Oral Squamous Cell Carcinoma. Oncology Reports, 25, 637-644..
|
[9]
|
Cadenas, C., Franckenstein, D., Schmidt, M., Gehrmann, M., Hermes, M., Geppert, B., et al. (2010) Role of Thiore-doxin Reductase 1 and Thioredoxin Interacting Protein in Prognosis of Breast Cancer. Breast Cancer Research, 12.
|
[10]
|
Yan, C., Shieh, B., Reigan, P., Zhang, Z., Colucci, M.A., Chilloux, A., et al. (2009) Potent Activity of Indolequinones against Human Pancreatic Cancer: Identification of Thioredoxin Reductase as a Potential Target. Molecular Pharmacology, 76, 163-172.
|
[11]
|
Singh, S.S., Li, Y., Ford III, O.H., Wrzosek, C.S., Mehedint, D.C., Titus, M.A., et al. (2008) Thioredoxin Reductase 1 Expression and Castration-Recurrent Growth of Prostate Cancer. Translational Oncology, 1, 153-157.
|
[12]
|
Cunnea, P., Fernandes, A.P., Capitanio, A., Eken, S., Spyrou, G. and Bjornstedt, M. (2007) Increased Expression of Specific Thioredoxin Family Proteins; A Pilot Immuno-histochemical Study on Human Hepatocellular Carcinoma. International Journal of Immunopathology and Pharma-cology, 20, 17-24.
|
[13]
|
Haapasalo, H., Kylaniemi, M., Paunu, N., Kinnula, V.L. and Soini, Y. (2003) Expression of Antioxidant Enzymes in Astrocytic Brain Tumors. Brain Pathology, 13, 155-164.
|
[14]
|
Biaglow, J.E. and Miller, R.A. (2005) The Thioredoxin Reductase/Thioredoxin System—Novel Redox Targets for Cancer Therapy. Cancer Biology & Therapy, 4, 6-13.
|
[15]
|
Luo, Y., Ma, W.W., Yang, J., Wu, L., Li, Y.Q., Zhao, Y.Y. and Zeng, H.H. (2012) Clinical Value of Thioredoxin Reductase Detection Kit for Diagnosis of Cancers. International Journal of Laboratory Medicine, 33, 13.
|
[16]
|
Zhang, X.T. and Xiong, Y.M. (2004) The Progress in Studies of Thioredoxin Reductase. Foreign Medical Sciences-Section of Medgeography, 25, 4.
|
[17]
|
Fernandes, A.P., Capitanio, A., Selenius, M., Brodin, O., Rundlof, A.K. and Bjornstedt, M. (2009) Expression Profiles of Thioredoxin Family Proteins in Human Lung Cancer Tissue: Correlation with Proliferation and Differentiation. Histopathology, 55, 313-320.
|
[18]
|
Sun, X.J., Dobra, K., Bjornstedt, M. and Hjerpe, A. (2000) Upregulation of 9 Genes, Including That for Thioredoxin, during Epithelial Differentiation of Mesothelioma Cells. Differentiation, 66, 181-188.
|
[19]
|
Rundlof, A.-K., Fernandes, A.P., Selenius, M., Babic, M., Shariatgorji, M., Nilsonne, G., et al. (2007) Quantification of Alternative mRNA Species and Identification of Thiore-doxin Reductase 1 Isoforms in Human Tumor Cells. Differentiation, 75, 123-132.
|
[20]
|
Takagi, Y., Gon, Y., Todaka, T., Nozaki, K., Nishiyama, A., Sono, H., et al. (1998) Expression of Thioredoxin Is Enhanced in Atherosclerotic Plaques and during Neointima Formation in Rat Arteries. Laboratory Investigation, 78, 957- 966.
|
[21]
|
Choi, H., Tostes, R.C. and Webb, R.C. (2011) Thioredoxin Reductase Inhibition Reduces Relaxation by Increasing Oxidative Stress and S-Nitrosylation in Mouse Aorta. Journal of Cardiovascular Pharmacology, 58, 522-527.
|
[22]
|
Schulze, P.C., Yoshioka, J., Takahashi, T., He, Z.H., King, G.L. and Lee, R.T. (2004) Hyperglycemia Promotes Oxidative Stress through Inhibition of Thioredoxin Function by Thioredoxin-Interacting Protein. Journal of Biological Chemistry, 279, 30369-30374.
|
[23]
|
Yamamoto, H., Miyake, Y., Noura, S., Ogawa, M., Yasui, M., Ikenaga, M., et al. (2001) Tumor Markers for Colorectal Cancer. Gan to Kagaku Ryoho Cancer & Chemotherapy, 28, 1299-1305.
|
[24]
|
Tamakoshi, K., Kikkawa, F., Shibata, K., Tomoda, K., Obata, N.H., Wakahara, F., et al. (1996) Clinical Value of CA125, CA19-9, CEA, CA72-4, and TPA in Borderline Ovarian Tumor. Gynecologic Oncology, 62, 67-72.
|
[25]
|
Ni, X.G., Bai, X.F., Mao, Y.L., Shao, Y.F., Wu, J.X., Shan, Y., et al. (2005) The Clinical Value of Serum CEA, CA19-9, and CA242 in the Diagnosis and Prognosis of Pancreatic Cancer. Ejso, 31, 164-169.
|
[26]
|
Ma, S., Shen, L., Qian, N. and Chen, K. (2011) The Prognostic Values of CA125, CA19.9, NSE, and SCC for Stage I NSCLC Are Limited. Cancer Biomarkers, 10, 155-162.
|
[27]
|
Imada, T., Rino, Y., Takahashi, M., Hatori, S., Shiozawa, M., Tanaka, J., et al. (1997) Expression of CA19-9, SLX, STN and CEA in Relatively Early Gastric Carcinoma. Oncology Reports, 4, 899-904.
|
[28]
|
Huang, M.-S., Jong, S.-B., Tsai, M.-S., Lin, M.-S., Chong, I.-W., Lin, H.-C., et al. (1996) Comparison of Cytokeratin Fragment 19 (CYFRA 21-1), Tissue Polypeptide Antigen (TPA) and Carcinoembryonic Antigen (CEA) as Tumor Markers in Lung Cancer. European Journal of Cancer, 32A.
|
[29]
|
Hanagiri, T., Sugaya, M., Takenaka, M., Oka, S., Baba, T., Shigematsu, Y., et al. (2011) Preoperative CYFRA 21-1 and CEA as Prognostic Factors in Patients with Stage I Non-Small Cell Lung Cancer. Lung Cancer, 74, 112-117.
|
[30]
|
Changchine, C.S., Yung, C.Y. and Tzen, K.Y. (1991) Serum Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen (CA 19-9) Values in Patients with Pancreatic Cancer or Pancreatitis. Chang Gung Medical Journal, 14, 32-38.
|
[31]
|
Yao, F., Guo, J.M., Xu, C.F., Lou, Y.L., Xiao, B.X., Zhou, W.H., et al. (2005) Detecting AFP mRIVA in Peripheral Blood of the Patients with Hepatocellular Carci-noma, Liver Cirrhosis and Hepatitis. Clinica Chimica Acta, 361, 119- 127.
|
[32]
|
Takeshima, N., Shimizu, Y., Umezawa, S., Hirai, Y., Chen, J.T., Fujimoto, I., et al. (1994) Combined Assay of Serum Levels of CA125 and CA19-9 in Endometrial Carcinoma. Gynecologic Oncology, 54, 321-326.
|
[33]
|
Danaei, G., Vander Hoorn, S., Lopez, A.D., Murray, C.J.L. and Ezzati, M. (2005) Comparative Risk Assessment C. Causes of Cancer in the World: Comparative Risk Assessment of Nine Behavioural and Environmental Risk Factors. Lancet, 366, 1784-1793.
|